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Predictors of Overall ST HR 95% CI p value
Recent MI up to 72 hours 2.66 1.52-4.66 0.001
Recent MI >72 hours 1.89 1.08-3.29 0.03
Multiple DES implanted 1.89 1.28-2.80 0.002
SVG 2.21 1.29-3.78 0.004
Residual stenosis (QCA analysis) 1.03 1.00-1.05 0.03
Predictors of Deﬁnite ST
Recent MI up to 72 hours 3.68 1.87-7.23 <0.001
Multiple DES implanted 2.24 1.30-3.86 0.004
SVG 2.62 1.32-5.22 0.006
Predictors of Early ST (up to 30 days)
OR 95% CI p value
Diabetes 2.45 0.014
Recent MI up to 72 hours 3.65 <0.001
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Background: Stent fracture is related to restenosis after drug-eluting stent (DES) im-
plantation. As percutaneous coronary intervention (PCI) cases for complex lesions
increased, those for stent fracture-related restenosis also increased. However, the optimal
PCI strategy for such restenosis remains unclear. We compared the results of PCI with
plain old balloon angioplasty (POBA), paclitaxel-coated balloon (PCB), and DES (siro-
limus-eluting stent, paclitaxel-eluting stent, zotarolimus-eluting stent, everolimus-eluting
stent, and biolimus-eluting stent) for restenosis with stent fracture after DES implantation.
Methods: From November 2002 to December 2012, 9357 patients with 15894 lesions
underwent DES implantation successfully. Of these, 12918 lesions were angio-
graphically followed up after 6 to 8 months (midterm f/u) and 9989 were followed up
at 12 months after midterm f/u. Stent fracture occurred in 576 (4.5%) of the 12918
lesions and restenosis with stent fracture occurred in 206 lesions. Restenosis with stent
fracture was deﬁned as a restenosis lesion within 5 mm from a stent fracture site. Of
the 206 lesions, target lesion revascularization by PCI with POBA, PCB, or DES was
performed on 124 lesions.
Results: Data are shown in the ﬁgure. At 2-year f/u, the cumulative incidence of re-
restenosis was signiﬁcantly lower after retreatment with DES than that with POBA
and PCB. In addition, late catch-up phenomenon was found after retreatment with
PCB.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/CoConclusions: Retreatment with DES could be an acceptable treatment for restenosis
with stent fracture after DES implantation.
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Background: Presence of stent fracture (SF) after sirolimus-eluting stent (SES) im-
plantation has reported to be associated with an increased risk of adverse events and
those are previously reported. But little is known about the outcomes after re-inter-
vention for SES restenosis lesion with SF.
Methods: From April 2007 to August 2011, total 2059 lesions implanted SES during
PCI at our hospital. Total 228 lesions, 11.1% had restenosis (deﬁned as %diameter
stenosis >50%) in follow-up angiogram until March 2013. Subjects of the study were
49 lesions 42 patients those implanted SES for denovo coronary artery stenosis and in-
stent restenosis with SF was documented in follow-up angiogram. SF was deﬁned as
complete or partial separation of the stent as assessed by plain ﬂuoroscopy. During the
target lesion revascularization procedure, 14 lesions implanted everolimus-eluting
stent (EES group), 20 lesions implanted sirolimus- and paclitaxel-eluting stent,
stainless steel stent with durable polymer (SS group). And also 15 lesions were dilated
with balloon angioplasty alone (POBA group). We compared the outcomes of
3 groups retrospectively.
Results: Baseline characteristics were similar. One-year cumulative incidence of
restenosis after repeat intervention those calculated by Kaplan-Meier methods were
EES group 22%, SS group 66% and POBA group 76%, respectively. EES group
signiﬁcantly reduced the cumulative incidence of restenosis after repeat intervention
(versus SS group; p¼0.0471 and POBA group; p¼0.0085).
Conclusions: For reduction in incidence of re-restenosis for the SES restenosis lesion
with SF during 1-year after repeat intervention, cobalt chromium EES implantations
were superior to stainless steel stent with durable polymer or balloon angioplasty
alone.
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Background: Stent fracture (SF) is an unresolved, clinically relevant issue, even in
the newer-generation drug-eluting stent era. The PROMUS Element platinum-chro-
mium everolimus-eluting stent (PtCr-EES; Boston Scientiﬁc, Natick, Massachusetts)
is designed to provide the improved fracture resistance, whereas the incidence and
clinical impact of SF after PtCr-EES implantation remains unclear. The aim of this
study was to assess the incidence and clinical impact of SF after PtCr-EES
implantation.
Methods: Between March 2012 and June 2013, a total of 676 patients with 839 le-
sions undergoing PtCr-EES implantation and follow-up angiography within 9 months
after index procedure were analyzed. SF was deﬁned as complete or partial separation
of the stent, as assessed by plain ﬂuoroscopy, intravascular ultrasound, or optical
coherence tomography during the follow-up. We assessed the rate of SF and the
cumulative incidence of clinically-driven target lesion revascularization and deﬁnite
stent thrombosis within 9 months.
Results: SF was observed in 12 of 839 lesions (1.4%) and 12 of 676 patients (1.7%).
Cumulative incidence of clinically-driven target lesion revascularization within 9
months was numerically higher in the SF group than that in the non-SF group (25.0%
versus 2.4%). Cumulative incidence of deﬁnite early and late stent thrombosis within
9-month was similar between the SF and non-SF groups (0.0% versus 0.2%).
Conclusions: SF after PtCr-EES occurs in 1.4% of lesions and appears to be asso-
ciated with clinically-driven target lesion revascularization.
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